MD Conference Express ESC 2012 - (Page 35)
Take our survey and get access to a free eBook!
than eplerenone. This agent drug is being evaluated to determine its safety and efficacy, with serum potassium levels as one outcome measure [NCT01345656]. Aliskiren is the first orally active direct renin inhibitor, and it has been evaluated in several studies, including comparisons with placebo, with enalapril monotherapy and in combination with enalapril [Gheorghiade M et al. Eur J Heart Fail 2011; Krum H et al. Eur J Heart Fail 2011]. Dr. Teerlink noted that aliskiren was found to be associated with an increased risk for adverse events in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints [ALTITUDE] trial, which involved patients with type 2 diabetes at high risk for CV and renal events [Parving HH et al. 2012 ESC Hot Line; see page 13 of this report]. Among the vasodilating neurohormones being evaluated as treatment for HF is LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, which led to significant improvement in N-terminal prohormone brain natriuretic peptide in the Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction [PARAMOUNT] trial [Solomon SD et al. Lancet 2012; see page 11 of this report]. LCZ696 is being compared with enalapril in the ongoing Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients with Chronic Heart Failure [PARADIGM-HF; NCT01035255] trial. Relaxin is a vasoactive neurohormone that has been shown to relieve dyspnea and improve congestion and possibly decrease 60-day mortality or HF-related hospitalization [Teerlink JR et al. Lancet 2009]. Updated results of the Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure [RELAX-AHF; NCT00520806] trial are scheduled to be presented at the American Heart Association Scientific Sessions in November 2012. New inotropes in development are stresscopin; CXL1020, a nitroxyl donor; and omecamtiv mecarbil, a myosin activator. More studies are needed to determine the safety and efficacy of these drugs for patients with HF. The heart rate modulator ivabradine significantly reduced risk (18%; p<0.0001) of CV death or hospitalization for worsening HF, in patients with symptomatic HF (NYHA class II-IV) and LVEF ≤35%, who were in sinus rhythm with a heart rate ≥70 beats per minute [Swedberg K et al. Lancet 2010]. Dr. Teerlink noted that treatment with a b-blocker should be maximized before treatment with ivabradine is started. Ventricular Assist Devices Only a fraction of patients eligible for a left ventricular assist device (LVAD) receive one, said Antonios Pitsis,
MD, Thessaloniki Heart Institute, Thessaloniki, Greece. However, improved outcomes with later generation devices and the United States Food and Drug Administration approval of the HeartMate II as destination therapy have increased the number of destination therapy implantations 10-fold since January 2010. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure [REMATCH] trial was the first study to compare an assist device with medical therapy, and the device led to a doubling of 1-year survival (from 25% to 52%) [Rose EA et al. N Engl J Med 2001]. Newer continuous-flow devices have been associated with better 2-year survival and lower rates of disabling stroke and reoperation than with pulsatile-flow devices [Slaughter MS et al. N Engl J Med 2009], as well as with clinically relevant improvements in functional capacity and HF-related QoL [Rogers JG et al. J Am Coll Cardiol 2010]. According to the Fourth Annual Report of the Interagency Registry for Mechanically Assisted Circulatory Support [INTERMACS] annual report, the current actuarial survival with continuous-flow devices was 82% at 1 year and 74% at 2 years, compared with 61% and 43%, respectively, for pulsatile-flow devices [Kirklin JK et al. J Heart Lung Transplant 2012]. When used as destination therapy, the devices are associated with a 1-year survival rate of 74%. Defining patient profiles with regard to severity of disease is important when considering the use of an LVAD, and INTERMACS has categorized patients into 7 levels from “crash and burn” to advanced class III. Among the significant risk factors for death with destination therapy are an older age, critical cardiogenic shock, diabetes, pulmonary hypertension, high BUN level, low sodium level, concomitant surgery, use of a bi-VAD, and use of a pulsatile-flow device. Prof. Pitsis said that attempts are being made to implant VADs earlier, but he expressed caution about this approach until the results of the Randomized Evaluation of VAD Intervention Before Inotropic Therapy [REVIVE-IT; NCT01369407] trial are available. He added that patients with biventricular failure are still better treated with urgent heart transplantation. Better patient selection, management approaches, and technical advances will help to improve outcomes and decrease adverse events. Future efforts include further miniaturization of devices to allow for less invasive implantation, wider implementation of newer technologies to reduce anticoagulation, and partial support for patients with class IIIb disease who are exercise intolerant. Prof. Pitsis added that patients want a fully implantable device, and one should be available in the coming years.
35
Peer-Reviewed Highlights from the European Society of Cardiology Congress 2012
http://www.mdconferencexpress.com
http://www.surveymonkey.com/s/mdce_esc2012
Table of Contents for the Digital Edition of MD Conference Express ESC 2012
MD Conference Express ESC 2012
Contents
ESC 2012 Clinical Practice Guidelines
TAVI: 10 Years After the First Case
PARAMOUNT Trial Results
TRILOGY ACS Outcomes
Results from the ALTITUDE Trial
Results of the WOEST Trial
Results from the Aldo-DHF Trial
FAME 2 Results
Results from the IABP-SHOCK II Trial
STEMI Mortality Decreases in France While Some Key Risk Factors Increase
Results from the PURE Study
PURE: Treatment and Control of Hypertension
Genetic Determinants of Variability in Dabigatran Exposure
The RE-LY AF Registry
TRA 2°P-TIMI 50 Results
Rivaroxaban of Benefit in STEMI: ATLAS ACS 2-TIMI 51
Ivabradine Effect on Recurrent Hospitalization for HF
CLARIFY: Similar 1-Year Outcomes for Men and Women with Stable CAD
HPS2-THRIVE Study Results
PRoFESS Study Results
Outcomes from the CARDia Trial
Hypertension
Atrial Fibrillation
Heart Failure
MD Conference Express ESC 2012
https://www.nxtbook.com/nxtbooks/md_conference_express/esc2012
https://www.nxtbookmedia.com